{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125353","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.929125+00:00","generated_at":"2026-05-30T02:27:37.188223+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Perspective Therapeutics Q3 net loss $15.1M ($0.21/share); cash $267.8M funds into mid-2026","bullets":["Net loss from continuing and discontinued ops $15.1M vs $10.4M YoY; basic loss per share $0.21.","Cash, equivalents and short-term investments $267.8M (Sep 30, 2024) vs $9.2M at Dec 31, 2023.","R&D expense surged 114% to $12.0M; G&A expense up 56% to $7.0M; no product revenue.","Phase 1/2a trials advancing: VMT-α-NET and VMT01; combo cohort with nivolumab open.","Manufacturing capacity expanded: second cGMP facility in Somerset, NJ and three new buildings purchased."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125353","json":"https://secwatch.observer/filing/0000950170-24-125353.json","markdown":"https://secwatch.observer/filing/0000950170-24-125353.md","text":"https://secwatch.observer/filing/0000950170-24-125353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017024125353/0000950170-24-125353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017024125353/catx-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:27:37.188223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}